Cytokine Microdialysis for Real-Time Immune Monitoring in Glioblastoma Patients Undergoing Checkpoint Blockade

Trial Profile

Cytokine Microdialysis for Real-Time Immune Monitoring in Glioblastoma Patients Undergoing Checkpoint Blockade

Recruiting
Phase of Trial: Phase I

Latest Information Update: 08 Aug 2018

At a glance

  • Drugs Nivolumab (Primary) ; Relatlimab (Primary)
  • Indications Glioblastoma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 04 Aug 2018 Planned initiation date (estimated date for recruitment of the first subject) changed from 3 Aug 2018 to 9 Aug 2018.
    • 28 Jul 2018 Planned initiation date (estimated date for recruitment of the first subject) changed from31 Jul 2018 to 3 Aug 2018.
    • 25 Jul 2018 Planned initiation date (estimated date for recruitment of the first subject) changed from 23 Jul 2018 to 31 Jul 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top